ISSN 2306-5559 (print)
ISSN 2410-938X (online)
ISSN 2410-938X (online)
Отсутствует
интервенционный кардиолог, аритмолог; PhD докторант кафедры политики и организации здравоохранения; старший преподователь кафедры клинических дисциплин
1. Benjamin EJ, Muntner P, Alonso A, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2019 update: a report from the American Heart Association. Circulation 2019;139:e56-528.2. Li KHC, White FA, Tipoe T, et al. The current state of mobile phone apps for monitoring heart rate, heart rate variability, and atrial fibrillation: narrative review. JMIR Mhealth Uhealth 2019;7:e11606.3. Halcox JPJ, Wareham K, Cardew A, Gilmore M, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF Study. Circulation 2017;136:1784-94.4. Freedman B, Camm J, Calkins H, et al, SCREEN CollaboratorsAF. Screening for atrial fibrillation: a report of the AF- SCREEN International Collaboration. Circulation 2017;135:1851-67.5. Magnussen C, Niiranen TJ, Ojeda FM, et al, BiomarCaRE Consortium. Sex dif- ferences and similarities in atrial fibrillation epidemiology, risk factors, and mor- tality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation 2017;136: 1588-97.6. Kotecha D, Lam CS, Van Veldhuisen DJ, et al. Heart failure with preserved ejec- tion fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 2016;68:2217- 28.7. Blum S, Muff C, Aeschbacher S, et al. Prospective assessment of sex-related dif- ferences in symptom status and health perception among patients with atrial fibril- lation. J Am Heart Assoc 2017;6:e005401.8. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associat- ed with atrial fibrillation: a meta-analysis. Ann Intern Med 2013;158:338-46.9. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313-20.10. Meyre P, Blum S, Berger S, et al. Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta- analysis. Can J Cardiol 2019;35:1332- 43.11. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) [published online ahead of print, 2020 Aug 29]. Eur Heart J. 2020;ehaa612. doi:10.1093/eur- heartj/ehaa612.12. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A novel approach to in-depth characterization (rather than Classification) of atrial fibrillation. Thromb Haemost 2020; doi: 10.1055/s-0040-1716408.13. Lip GYH. The ABC pathway: an integrated approach to improve AF manage- ment. Nat Rev Cardiol 2017;14:627-28.14. Proietti M, Romiti GF, Olshansky B, et al. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med 2018;131:1359-1366.15. Yoon M, Yang PS, Jang E, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. Thromb Haemost 2019;19:1695-703.16. Pastori D, Farcomeni A, Pignatelli P, et al. ABC (Atrial fibrillation Better Care) pathway and healthcare costs in atrial fibrillation: the ATHEROAF study. Am J Med 2019;132:856-61.17. Pastori D, Pignatelli P, Menichelli D, et al. Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (Atrial fibrillation Better Care) pathway in the ATHERO-AF study cohort. Mayo Clin Proc 2019;94:1261-6718. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708930/ Table 1.19.Wu VC, Wu M, Aboyans V, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart 2020;106:534-40.20.Nielsen PB, Skjoth F, Overvad TF, et al. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation 2018;137:832-40.21.Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem 2017;63:152-64.22.Hijazi Z, Lindback J, Alexander JH, et al.; ARISTOTLE and STABILITY Inves- tigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomark- er-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37:1582- 90.23.Shin SY, Han SJ, Kim JS, et al. Identification of markers associated with devel- opment of stroke in ‘clinically low-risk’ atrial fibrillation patients. J Am Heart Assoc 2019;8:e012697.24.Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118:2171-87.25.Chao TF, Lip GYH, Lin YJ, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018;118:768-77.26. https://www.chil.kz/Aux/EditionDownload/166 Man-Medicine Kazakhstan, №10 (154) Сardiology, rheumatology, page 25, figure 2.27.ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of VascularEvents (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.28.Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014;16:631-8.29.Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safe- ty of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.30.Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013;144:1555-63.31.Camm AJ, Amarenco P, Haas S, et al; XANTUS Investigators. XANTUS: a real- world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-53.32.Martinez CAA, Lanas F, Radaideh G, et al; XANTUS Investigators. XANTUS- EL: a real-world, prospective, observational study of patients treated with rivarox- aban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J 2018;70:307-13.33.Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’ clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017;117:1072- 82.34.Kirchhof P, Radaideh G, Kim Y-H, et al. Global prospective safety analysis of rivaroxaban. J Am Coll Cardiol 2018;72:141-53.35.Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvu- lar atrial fibrillation. N Engl J Med 2011;365:883-91.36.Ingrasciotta Y, Crisafulli S, Pizzimenti V, Marciano I, Mancuso A, Ando G, Corrao S, Capranzano P, Trifiro G. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol 2018;14:1057-69.37.Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non- vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93.38.Moiseev S, Kiyakbaev GG, Fomin VV. Novel oral anticoagulants in prevention of stroke in patients with atrial fibrillationa and chronic kidney disease. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther 2015;3:5-11 (In Russ.).39.Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020;106(5):358-64.40.Gu ZC, Kong LC, Yang SF, et al. Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials. Cardiovasc Diagn Ther 2019;9:410-9.41.Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban comparedwith warfarin: insights from ROCKET AF. Circulation 2016;134:37–47.42.https://www.chil.kz/Aux/EditionDownload/166 Man-Medicine Kazakhstan, №10 (154) Сardiology, rheumatology, page 28, table 3, рage 30, table 4.